反应详情

Essentially following the procedures described for Example 93, but using 5′-amino-4′-chloro-3-methyl-spiro[imidazolidine-4,2′-indane]-2,5-dione, enantiomer B, (described in Intermediate 49) in place of 5′-amino-6′-chloro-3-methyl-spiro[imidazolidine-4,2′-indane]-2,5-dione, enantiomer B, the title compound was obtained. MS: m/z=517 (M+1). HRMS: m/z=517.1381; calculated m/z=517.1386 for C26H22ClN6O4.